184 related articles for article (PubMed ID: 10460662)
1. p53 expression in phyllodes tumours is associated with histological features of malignancy but does not predict outcome.
Feakins RM; Mulcahy HE; Nickols CD; Wells CA
Histopathology; 1999 Aug; 35(2):162-9. PubMed ID: 10460662
[TBL] [Abstract][Full Text] [Related]
2. Malignant phyllodes tumours of the breast display increased stromal p53 protein expression.
Millar EK; Beretov J; Marr P; Sarris M; Clarke RA; Kearsley JH; Lee CS
Histopathology; 1999 Jun; 34(6):491-6. PubMed ID: 10383692
[TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast.
Feakins RM; Wells CA; Young KA; Sheaff MT
Hum Pathol; 2000 Oct; 31(10):1214-22. PubMed ID: 11070114
[TBL] [Abstract][Full Text] [Related]
4. 2005 Galloway Memorial Lecture: Breast phyllodes tumours--morphology and beyond.
Tan PH
Ann Acad Med Singap; 2005 Dec; 34(11):671-7. PubMed ID: 16453039
[TBL] [Abstract][Full Text] [Related]
5. Phyllodes tumor of the breast: stromal overgrowth and histological classification are useful prognosis-predictive factors for local recurrence in patients with a positive surgical margin.
Taira N; Takabatake D; Aogi K; Ohsumi S; Takashima S; Nishimura R; Teramoto N
Jpn J Clin Oncol; 2007 Oct; 37(10):730-6. PubMed ID: 17932112
[TBL] [Abstract][Full Text] [Related]
6. Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours.
Tse GM; Chaiwun B; Lau KM; Scolyer R; Lee CS; Karim RZ; Putti TC; Law BK; Lui PC; Tan PH
J Clin Pathol; 2007 Sep; 60(9):1051-6. PubMed ID: 17158636
[TBL] [Abstract][Full Text] [Related]
7. Mammary fibroadenoma and some phyllodes tumour stroma are composed of CD34+ fibroblasts and factor XIIIa+ dendrophages.
Silverman JS; Tamsen A
Histopathology; 1996 Nov; 29(5):411-9. PubMed ID: 8951485
[TBL] [Abstract][Full Text] [Related]
8. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.
Yonemori K; Hasegawa T; Shimizu C; Shibata T; Matsumoto K; Kouno T; Ando M; Katsumata N; Fujiwara Y
Pathol Res Pract; 2006; 202(10):705-12. PubMed ID: 16889904
[TBL] [Abstract][Full Text] [Related]
9. In phyllodes tumour of the breast expression of c-kit but not of ALDH1A1 is associated with adverse clinico-pathological features.
Chougule A; Bal A; Das A; Kohli PS; Singh G
Virchows Arch; 2016 Dec; 469(6):651-658. PubMed ID: 27696244
[TBL] [Abstract][Full Text] [Related]
10. Phyllodes tumour of the breast: immunohistochemical study of 37 tumours using MIB1 antibody.
Kocová L; Skálová A; Fakan F; Rousarová M
Pathol Res Pract; 1998; 194(2):97-104. PubMed ID: 9584322
[TBL] [Abstract][Full Text] [Related]
11. Tumour angiogenesis and p53 protein expression in mammary phyllodes tumors.
Tse GM; Lui PC; Scolyer RA; Putti TC; Kung FY; Law BK; Lau TS; Lee CS
Mod Pathol; 2003 Oct; 16(10):1007-13. PubMed ID: 14559983
[TBL] [Abstract][Full Text] [Related]
12. Phyllodes tumours of the breast: the role of CD34, vascular endothelial growth factor and β-catenin in histological grading and clinical outcome.
Ho SK; Thike AA; Cheok PY; Tse GM; Tan PH
Histopathology; 2013 Sep; 63(3):393-406. PubMed ID: 23772632
[TBL] [Abstract][Full Text] [Related]
13. Phyllodes tumours of the breast - differentiating features in core needle biopsy.
Tsang AK; Chan SK; Lam CC; Lui PC; Chau HH; Tan PH; Tse GM
Histopathology; 2011 Oct; 59(4):600-8. PubMed ID: 21916949
[TBL] [Abstract][Full Text] [Related]
14. E-cadherin expression in the epithelial components of mammary phyllodes tumors.
Tsang JY; Mendoza P; Putti TC; Karim RZ; Scolyer RA; Lee CS; Pang AL; Tse GM
Hum Pathol; 2012 Dec; 43(12):2117-23. PubMed ID: 22820000
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Singapore nomogram for outcome prediction in breast phyllodes tumours in a large patient cohort.
Chng TW; Gudi M; Lim SH; Li H; Tan PH
J Clin Pathol; 2018 Feb; 71(2):125-128. PubMed ID: 28751520
[TBL] [Abstract][Full Text] [Related]
16. ER, p53 and MIB-1 are significantly associated with malignant phyllodes tumor.
Munawer NH; Md Zin R; Md Ali SA; Muhammad R; Ali J; Das S
Biomed J; 2012; 35(6):486-92. PubMed ID: 23442362
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of epithelial-mesenchymal transition proteins Twist and Foxc2 in phyllodes tumours of the breast.
Lim JC; Koh VC; Tan JS; Tan WJ; Thike AA; Tan PH
Breast Cancer Res Treat; 2015 Feb; 150(1):19-29. PubMed ID: 25677742
[TBL] [Abstract][Full Text] [Related]
18. Nuclear survivin expression in stromal cells of phyllodes tumors and fibroadenomas of the breast.
Hirano H; Matsushita K; Okimura A; Yoshida T; Kizaki T; Ito T
Anticancer Res; 2014 Mar; 34(3):1251-3. PubMed ID: 24596368
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic analysis of benign, borderline and malignant phyllodes tumors of the breast].
Wang H; Wang X; Wang C
Zhonghua Zhong Liu Za Zhi; 2015 Dec; 37(12):923-7. PubMed ID: 26887622
[TBL] [Abstract][Full Text] [Related]
20. Increased microvessel density in malignant and borderline mammary phyllodes tumours.
Tse GM; Ma TK; Chan KF; Law BK; Chen MH; Li KH; Chan EC; Mak MK
Histopathology; 2001 Jun; 38(6):567-70. PubMed ID: 11422501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
